Aveo Pharmaceuticals Inc. is committed to bringing innovative therapies to patients in need. With a strong corporate philosophy centered around advancing the treatment landscape, Aveo strives to develop targeted medicines addressing unmet medical needs. The company's dedication to improving patient outcomes is reflected in its focus on precision medicine and personalized therapies. Aveo prioritizes collaboration and actively seeks strategic partnerships to accelerate the development and commercialization of its novel drug candidates. By maintaining a patient-centric approach and embracing scientific excellence, Aveo Pharmaceuticals Inc. positions itself as a leader in the biopharmaceutical industry.

Aveo Pharmaceuticals Inc is primarily present in the United States.

Aveo Pharmaceuticals Inc has achieved several significant milestones in its journey. One of the major accomplishments includes the approval of their lead product, Tivozanib, by the U.S. Food and Drug Administration (FDA) for advanced renal cell carcinoma patients. Additionally, Aveo Pharmaceuticals Inc has successfully partnered with multinational companies, such as EUSA Pharma and Biodesix, to commercialize and expand the reach of their innovative therapies. The company has also made remarkable progress in their clinical development program, further demonstrating the potential of their pipeline candidates. Aveo Pharmaceuticals Inc continues to thrive by consistently advancing its research and development efforts to bring novel solutions to patients in need.

Aveo Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development and commercialization of targeted cancer therapies. Founded in 2002 and headquartered in Cambridge, Massachusetts, Aveo has a rich history in the field of oncology. The company has been dedicated to discovering and developing innovative therapies to improve the lives of cancer patients. Aveo has collaborated with various partners and achieved significant milestones in its journey. With a commitment to advancing precision medicine, Aveo continues to make strides towards the development of novel treatment options for cancer patients worldwide.

The main competitors of Aveo Pharmaceuticals Inc in the market are Bristol-Myers Squibb Company, Novartis AG, and Pfizer Inc.

Aveo Pharmaceuticals Inc is primarily active in the biopharmaceutical industry.

Aveo Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development and commercialization of targeted cancer therapies. Their business model revolves around researching, discovering, and advancing innovative medicines that address unmet medical needs for cancer patients. Aveo Pharmaceuticals Inc seeks to develop therapies that target and inhibit specific pathways involved in tumor growth and multiplication. By identifying and developing potential treatments, Aveo Pharmaceuticals aims to improve patient outcomes and provide better options for cancer treatment.

Το Ρ/Ε δεν μπορεί να υπολογιστεί αυτή τη στιγμή για το Aveo Pharmaceuticals.

Το KUV δεν μπορεί να υπολογιστεί αυτή τη στιγμή για Aveo Pharmaceuticals.

Το AlleAktien Qualitätsscore για το Aveo Pharmaceuticals είναι 4/10.

Τα έσοδα δεν μπορούν να υπολογιστούν επί του παρόντος για Aveo Pharmaceuticals.

Τα κέρδη για τον Aveo Pharmaceuticals δεν μπορούν να υπολογιστούν αυτή τη στιγμή.

Aveo Pharmaceuticals Inc is a biopharmaceutical company focused on developing cancer medications. The company is based in Cambridge, Massachusetts and is led by a team of experienced professionals from the pharmaceutical industry.

Η Aveo Pharmaceuticals καταβάλλει μια διανομή της τάξεως των 0 USD διαμοιρασμένη σε δόσεις ετησίως.

Το μέρισμα δεν μπορεί να υπολογιστεί για το Aveo Pharmaceuticals αυτή τη στιγμή ή η εταιρεία δεν διανέμει μέρισμα.

Ο αριθμός ISIN της Aveo Pharmaceuticals είναι US0535883070.

Το WKN της Aveo Pharmaceuticals είναι A2P0CL.

Ο τίκερ της Aveo Pharmaceuticals είναι AVEO.

Κατά τους τελευταίους 12 μήνες η Aveo Pharmaceuticals κατέβαλε μια μέρισμα ύψους . Αυτό αντιστοιχεί σε απόδοση μερίσματος περίπου . Για τους επόμενους 12 μήνες, η Aveo Pharmaceuticals προβλέπεται να πληρώσει μέρισμα 0 USD.

Η απόδοση μερίσματος της Aveo Pharmaceuticals ανέρχεται σήμερα στο .

Aveo Pharmaceuticals πληρώνει τέταρτον διανεμητέου μισθό. Αυτή καταβάλλεται τους μήνες .

Η Aveo Pharmaceuticals πλήρωσε κάθε χρόνο μέρισμα μέσα στα τελευταία 0 έτη.

Για τους επόμενους 12 μήνες αναμένονται μερίσματα σε ύψος των 0 USD. Αυτό αντιστοιχεί σε απόδοση μερίσματος 0 %.

Το Aveo Pharmaceuticals ανατίθεται στον τομέα 'Υγεία'.

Για να λάβεις το τελευταίο μέρισμα των Aveo Pharmaceuticals από την 3/8/2024 με τιμή 0 USD, έπρεπε να έχεις τη μετοχή στο χαρτοφυλάκιο σου πριν από την ημέρα Ex-Tag στις 3/8/2024.

Η τελευταία μερίσματος έγινε στις 3/8/2024.

Το έτος 2023, η Aveo Pharmaceuticals διένειμε 0 USD ως μερίσματα.

Τα μερίσματα του Aveo Pharmaceuticals καταβάλλονται σε USD.